Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.

ABSTRACT:

Background

While immune checkpoint inhibitors (ICIs) have been revolutionary in the treatment of cancer, their administration has been associated with a variety of immune-related adverse events (irAEs), including myasthenia gravis (MG), and Lambert-Eaton myasthenic syndrome (LEMS).

Objective

To provide a comprehensive synthesis of the evidence supporting an etiological role for ICIs in MG and LEMS in patients with no prior history of autoimmune disease.

Hypothesis

ICIs may trigger MG and LEMS in patients with no prior susceptibility to autoimmune disease.

Methods

Relevant primary research on Medline was interrogated using a series of search algorithms. Search terms were constructed based on the PICOS tool endorsed by the Cochrane Collaboration, which describes

SUBMITTER: Seligman C 

PROVIDER: S-EPMC9868566 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature